Immuneo Therapeutics investment opportunity

Company Overview

We are developing and optimizing a bioinformatic platform focused on personalized cancer therapies through patient neoepitopes identification. By combining tumor sequencing data and explainable AI epitope prediction model, our platform enables the selection of immunogenic targets.

We are initiating preclinical validation and preparing for Phase I clinical trial. This makes a perfect opportunity to join at a critical value inflection point.

Why invest?

Cancer immunotherapy market is growing due to significant degree of innovation, advancements include targeted therapies, and precision medicine. Techniques, such as next-generation sequencing and bioinformatics, have enabled the identification and characterization of tumor-specific antigens and the design of more precise and effective vaccines. The market is projected to double its actual value.

We have proven the concept efficiency in two case reports in different cancer type. We have successfully improved the patient situation where the overall survival was significantly increased in breast cancer report and the cancer prognosis was improved in pancreatic cancer report.

We have patented a list of T-Cell immunogenic peptides of Covid-19 tested in mouse. It is an example of other application of Immuneo Therapeutic pipeline for infectious disease and in future pandemies.

Our laboratory team is developing the preclinical phase in a highly structured plan (following the scientific advise of EMA) to quick follow the strategic roadmap in Clinical trial Phase I, in cooperation with the University Clinic in Brandenburg.

We are optimizing and validating our proprietary exAI-driven neo-epitope prediction pipeline, automatized and fully integrated form data input to epitope selection output. It modular architecture makes it scalable and adaptable to multiple cancer types and infectious diseases.

Funding requirements

Our target is to raise between 1M-2M€ in the next 3 years. The founding will be applied on the following:

• Bioinformatic optimization of the BITAP platform.

• Execution of planned non-clinical experiments in preparation for a Phase I clinical trial.

• Optimization and manufacturing of the BITAP Immunization formulation.

• Continuous regulatory consultation, strategic hires and company expansion.

We are actively seeking international clinical and research and development partners and we are open to expand operations to other countries that will increase genetic and clinical diversity, increment our network that can accelerate regulatory approvals across regions and enable broader B2B partnerships with hospital, clinic and biotech institutions.

Our output strategy:

We plan to:

1. Provide our bioinformatic service to personalized therapy in cancer with our BITAP platform.

2. Completion of clinical experiments as per regulatory requirements in preparation for a clinical Phase I in metastatic pancreatic adenocarcinoma with BITAP Immunization.